Please login to the form below

Not currently logged in
Email:
Password:

Symkevi

This page shows the latest Symkevi news and features for those working in and with pharma, biotech and healthcare.

Vertex’s triple combination CF therapy to become available on the NHS

Vertex’s triple combination CF therapy to become available on the NHS

Last October, the three parties finally reached an agreement for access to Vertex’s other cystic fibrosis drugs Orkambi (lumacaftor/ivacaftor), Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor). ... It’s also great news that more mutations have

Latest news

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    of CF patients and now Symkevi (ivacaftor and tezacaftor). This is effective for people who have two copies of the F508del mutation plus those with one of 14 other mutations.

  • The Orkambi row explained The Orkambi row explained

    It refuses to file Symkevi with NICE, stating that it will only submit its data if NICE updates its appraisal process. ... December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines

  • The Orkambi blame game The Orkambi blame game

    price of its existing CF treatments Kalydeco and Orkambi, as well as new combination Symkevi and any subsequent products.

  • #OrkambiNow? #OrkambiNow?

    The US company, based in Cambridge, Massachusetts is a pioneer of groundbreaking ‘precision medicine’ drugs against cystic fibrosis Kalydeco (launched in 2012) and Orkambi (2015) and now Symkevi (2018). ... The hope is that both sides can come to a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...